Literature DB >> 8370665

T cell receptor-extracellular constant regions as hetero-cross-linkers for immunoglobulin variable regions.

H Seimiya1, M Naito, T Mashima, H Yasui, Y Kuwana, Y Kurosawa, T Tsuruo.   

Abstract

The T cell receptor alpha and beta chains are covalently linked via a disulfide bond in their extracellular constant regions. To use these domains as specific hetero-cross-linkers of two different polypeptides, we created genetic constructs encoding a chimeric antibody Fab fragment in which mouse immunoglobulin constant regions from a phosphorylcholine-specific antibody were substituted for human alpha beta-T cell receptor (TCR) extracellular constant regions (for solubilization, the transmembrane- and cytoplasmic-regions of the receptor were deleted). These constructs, i.e., chimeric heavy (VHC beta C kappa) and light (VLC alpha) chains, were cotransfected into murine SP2/0 myeloma cells for expression. Cells transfected with the genes expressed mRNAs for chimeric heavy and light chains. Without CD3 molecules, the two chimeric chains specifically associated via a disulfide bond to form a chimeric Fab fragment in the cells. These data indicate that the TCR C alpha- and C beta-regions might be used as potent specific hetero-cross-linkers for protein engineering.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370665     DOI: 10.1093/oxfordjournals.jbchem.a124104

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  2 in total

1.  Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.

Authors:  Xiufeng Wu; Arlene J Sereno; Flora Huang; Kai Zhang; Micheal Batt; Jonathan R Fitchett; Dongmei He; Heather L Rick; Elaine M Conner; Stephen J Demarest
Journal:  MAbs       Date:  2015       Impact factor: 5.857

2.  EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies.

Authors:  Heather A Cooke; Joe Arndt; Chao Quan; Renée I Shapiro; Dingyi Wen; Susan Foley; Malgorzata M Vecchi; Martin Preyer
Journal:  MAbs       Date:  2018-09-20       Impact factor: 5.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.